Market capitalization | $32.41b |
Enterprise Value | $29.34b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 18.17 |
P/S ratio (TTM) P/S ratio | 20.07 |
P/B ratio (TTM) P/B ratio | 7.60 |
Revenue growth (TTM) Revenue growth | 101.07% |
Revenue (TTM) Revenue | $1.61b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
32 Analysts have issued a argenx SE ADR forecast:
32 Analysts have issued a argenx SE ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 1,615 1,615 |
101%
101%
|
|
Gross Profit | 1,336 1,336 |
112%
112%
|
|
EBITDA | -285 -285 |
38%
38%
|
EBIT (Operating Income) EBIT | -397 -397 |
30%
30%
|
Net Profit | -205 -205 |
49%
49%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
Head office | Netherlands |
CEO | Tim Hauwermeiren |
Employees | 1,148 |
Founded | 2008 |
Website | www.argen-x.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.